Research Topics
| Roberto J FirpiSummaryAffiliation: University of Florida Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantationRoberto J Firpi
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610 0214, USA
Liver Transpl 12:51-7. 2006..In conclusion, Cyclosporine may offer an advantage to Tacrolimus in those patients undergoing interferon-based therapy and should be studied in a prospective randomized trial...
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot studyRoberto J Firpi
Division of Gastroenterology, Hepatology and Nutrition, Section of Hepatobiliary Diseases and Liver Transplantation, Department of Medicine, University of Florida, Gainesville, FL 32610 0214, USA
Dig Dis Sci 55:196-203. 2010..We performed a pilot study to prospectively determine the antiviral effect of cyclosporine during therapy with PEGalfa-2a and ribavirin in liver transplant recipients with recurrent HCV infection...- Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infectionRoberto J Firpi
Section of Hepatobiliary Diseases, Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, PO Box 100214, JHMHC, Gainesville, FL 32610 0214, USA
Liver Transpl 9:57-61. 2003..The most common side effects were headache, nausea, and diarrhea. Mycophenolate alone does not appear to have a significant antiviral or biochemical effect in patients with chronic hepatitis C... - The natural history of hepatitis C cirrhosis after liver transplantationRoberto J Firpi
Section of Hepatobiliary Diseases, Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL 32610 0214, USA
Liver Transpl 15:1063-71. 2009..The Model for End-Stage Liver Disease can stratify risk for decompensation and survival, whereas successful antiviral therapy may be protective... - One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infectionRoberto J Firpi
Division of Gastroenterology, Hepatology, and Nutrition Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610 0214, USA
Liver Transpl 10:1240-7. 2004..A liver biopsy performed at 1 year posttransplant can help identify those patients more likely to develop progressive disease and may allow better targeting of antiviral therapy... - Management of viral hepatitis in hematologic malignanciesRoberto J Firpi
Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida Gainesville, FL 32610 0214, USA
Blood Rev 22:117-26. 2008..In this review we will highlight the mechanisms of virus reactivation, clinical manifestations, and management strategies to minimize acute and chronic morbidity in this population... - Current and future hepatitis C therapiesRoberto J Firpi
Section of Hepatobiliary Diseases and Liver Transplantation, Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Florida, Gainesville, Florida 32610 0214, USA
Arch Med Res 38:678-90. 2007..This review will focus on current therapies for hepatitis C and the most recent advances in the search for new therapies... - Short recovery time after percutaneous liver biopsy: should we change our current practices?Roberto J Firpi
Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases, University of Florida, 1600 SW Archer Road, PO Box 100214, Gainesville, FL 32610 0214, USA
Clin Gastroenterol Hepatol 3:926-9. 2005..The aim of this study was to determine whether ambulatory patients requiring percutaneous liver biopsy can be safely discharged after a short recovery time period... - Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis CManal F Abdelmalek
Department of Medicine, Section of Hepatobiliary Diseases University of Florida, Gainesville, FL 32610 0214, USA
Liver Transpl 10:199-207. 2004..05). In conclusion, loss of HCV after treatment of recurrent chronic hepatitis C with interferon and ribavirin is durable, and the durability of the SVR is associated with improvement in hepatic inflammation and regression of fibrosis... - Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis CRoberto J Firpi
Department of Medicine, Section of Hepatobiliary Diseases, University of Florida, Gainesville, FL 32610, USA
Liver Transpl 8:1000-6. 2002..In summary, combination therapy is a reasonable antiviral option for recurrent HCV infection for established post-LT hepatitis and appears to prevent histological progression of disease if viral eradication is successful... - Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantationVictor I Machicao
Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL 32610-0214, USA
Liver Transpl 12:754-61. 2006..In conclusion, the implementation of the MELD allocation system is not associated with increased mortality or occurrence of CRD-3 or CRD-4 in the first 2 years after LT... - Late presentation of a biliary tract complication after right hepatic donation resulting in secondary biliary cirrhosisGiuseppe Morelli
Division of Gastroenterology and Hepatology and Nutrition Section of Biliary Diseases and Liver Transplantation, University of Florida, Gainesville, FL 32610-0214, USA
Liver Transpl 12:306-9. 2006 
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplantRoberto J Firpi
Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition Section of Hepatobiliary Diseases and Liver Transplantation, University of Florida, Gainesville, Florida, USA
Liver Int 33:72-8. 2013..We sought to examine the role of IL-28B polymorphisms of donor and recipients in liver transplant patients with recurrent HCV and its impact on the response to interferon-based therapy...- Management of recurrent hepatitis C infection after liver transplantationAlpna R Limaye
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida College of Medicine, Gainesville, USA
Clin Liver Dis 15:845-58. 2011..This patient population is in need of new therapeutic options, and it remains to be seen whether direct-acting antiviral agents will be the answer to this ongoing therapeutic question... - Is early recurrence of hepatitis C associated with biliary anastomotic stricture after liver transplantation?Shiro Fujita
Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32610 0286, USA
Transplantation 84:1631-5. 2007..The aim of the current study is to determine if recurrence of hepatitis C affects biliary complications after LT, with special reference to late biliary anastomotic strictures (LBAS)... - An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infectionRoniel Cabrera
Section of Hepatobiliary Diseases, Department of Medicine, University of Florida, Gainesville, FL 32610-0214, USA
Hepatology 40:1062-71. 2004..In conclusion, CD4(+)CD25(+) T lymphocytes constitute a highly differentiated population and appear to play a role in viral persistence by suppressing HCV-specific T cell responses in a cell-cell contact manner... - Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantationHenry Chiu
Department of Medicine, University of Florida, Gainesville, Florida, USA
Liver Transpl 10:465-6. 2004 - Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis CMark W Russo
Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
Liver Transpl 11:1235-41. 2005..004). In conclusion, hepatic stellate cell activation early after liver transplantation complements traditional testing for identifying liver transplant recipients with hepatitis C at greatest risk for developing advanced fibrosis... - Update on hepatitis B treatmentRoberto J Firpi
Center for Liver Diseases and Transplantation, Cedars-Sinai Medical Center, Los Angeles, California, USA
MedGenMed 4:9. 2002